Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120

Barclays analyst Matt Miksic has initiated coverage on Abbott Laboratories (NYSE: ABT) with an Overweight rating. The firm has set a price target of $120 for the company's stock.